Novartis AG EBITDA 2010-2023 | NVS
Novartis AG annual and quarterly EBITDA history from 2010 to 2023. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Novartis AG EBITDA for the quarter ending December 31, 2023 was $3.856B, a 36.06% increase year-over-year.
- Novartis AG EBITDA for the twelve months ending December 31, 2023 was $18.152B, a 21.74% increase year-over-year.
- Novartis AG 2023 annual EBITDA was $18.152B, a 21.74% increase from 2022.
- Novartis AG 2022 annual EBITDA was $14.911B, a 27.56% increase from 2021.
- Novartis AG 2021 annual EBITDA was $11.689B, a 28.2% decline from 2020.
Novartis AG Annual EBITDA
(Millions of US $) |
| 2023 |
$18,152 |
| 2022 |
$14,911 |
| 2021 |
$11,689 |
| 2020 |
$16,281 |
| 2019 |
$14,874 |
| 2018 |
$13,620 |
| 2017 |
$14,705 |
| 2016 |
$14,311 |
| 2015 |
$14,448 |
| 2014 |
$11,089 |
| 2013 |
$15,445 |
| 2012 |
$11,507 |
| 2011 |
$16,760 |
| 2010 |
$15,103 |
| 2009 |
$9,982 |
Novartis AG Quarterly EBITDA
(Millions of US $) |
| 2023-12-31 |
$3,856 |
| 2023-09-30 |
$4,624 |
| 2023-06-30 |
$4,773 |
| 2023-03-31 |
$4,899 |
| 2022-12-31 |
$2,834 |
| 2022-09-30 |
$3,591 |
| 2022-06-30 |
$4,127 |
| 2022-03-31 |
$4,359 |
| 2021-12-31 |
$2,562 |
| 2021-09-30 |
$3,233 |
| 2021-06-30 |
$3,479 |
| 2021-03-31 |
$2,415 |
| 2020-12-31 |
$7,945 |
| 2020-09-30 |
$254 |
| 2020-06-30 |
$2,352 |
| 2020-03-31 |
$2,744 |
| 2019-12-31 |
$3,771 |
| 2019-09-30 |
$3,731 |
| 2019-06-30 |
$2,663 |
| 2019-03-31 |
$2,242 |
| 2018-12-31 |
$3,053 |
| 2018-09-30 |
$2,239 |
| 2018-06-30 |
$2,484 |
| 2018-03-31 |
$2,447 |
| 2017-12-31 |
$3,538 |
| 2017-09-30 |
$2,357 |
| 2017-06-30 |
$2,280 |
| 2017-03-31 |
$1,922 |
| 2016-12-31 |
$3,155 |
| 2016-09-30 |
$3,777 |
| 2016-06-30 |
$3,559 |
| 2016-03-31 |
$3,820 |
| 2015-12-31 |
$1,677 |
| 2015-09-30 |
$3,589 |
| 2015-06-30 |
$3,790 |
| 2015-03-31 |
$4,067 |
| 2014-12-31 |
$2,351 |
| 2014-09-30 |
$3,906 |
| 2014-06-30 |
$4,359 |
| 2014-03-31 |
$3,933 |
| 2013-12-31 |
$3,707 |
| 2013-09-30 |
$3,655 |
| 2013-06-30 |
$3,993 |
| 2013-03-31 |
$4,090 |
| 2012-12-31 |
$2,715 |
| 2012-09-30 |
$4,180 |
| 2012-06-30 |
$4,302 |
| 2012-03-31 |
$3,880 |
| 2011-12-31 |
$3,063 |
| 2011-09-30 |
$4,379 |
| 2011-06-30 |
$4,705 |
| 2011-03-31 |
$4,613 |
| 2010-12-31 |
$3,381 |
| 2010-09-30 |
$3,824 |
| 2010-06-30 |
$3,626 |
| 2010-03-31 |
$4,272 |
| 2009-12-31 |
$2,637 |
| 2009-09-30 |
$3,248 |
| 2009-06-30 |
$2,914 |
| 2009-03-31 |
$2,895 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$194.425B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
